BOSTON and LONDON — November 4, 2025 — Leads & Copy — Akari Therapeutics, Plc (Nasdaq: AKTX) announced its abstract highlighting immune mechanism-of-action data for its novel ADC payload, PH1, is now available on the 40th Annual SITC Meeting website. The Company will present the abstract in oral and poster presentations at the SITC Annual Meeting being held November 5-9, 2025 in National Harbor, MD.
Akari is advancing a new class of immuno-oncology ADCs built on a novel PH1 payload, a spliceosome modulator. The full SITC abstract, which included 2 figures, is now available here. Akari investigates the mechanism behind preclinical colon tumor regressions induced by a Trastuzumab PH1 ADC with/without anti-PD-1 and contrasts that against a first-in-class ADC with a microtubule inhibitor payload. A higher rate of complete regressions in the PH1 ADC combination vs comparator ADC combination is attributed to an immune response stimulated by neoantigen, activation of antigen-presenting cells, B, and T-cells, and a mechanistic synergy between the PH1 payload and the checkpoint inhibitor.
Details for the poster and oral presentations are as follows: Poster Session: Exhibits & Poster Viewing 1 & 2 Date and Time: Friday, November 7, 2025,11:30 AM-12:15 PM ET and 5:35 PM-7:00 PM ET, respectively Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center; Oral Session: 302 Beyond Cytotoxic Chemotherapy: the Next Generation of ADCs for Immune Modulation Date and Time: Sunday, November 9, 2025, 11:05-11:20 AM ET Location: Gaylord National Resort and Convention Center – Ballroom Level – Potomac Ballroom.
For those registered to attend the conference, to schedule a meeting with Akari, contact AKTX@jtcir.com.
Jenene Thomas
JTC Team, LLC
908-824-0775
AKTX@jtcir.com
Source: Akari Therapeutics
